SRF: Citi maintains a Sell on SRF with a Target Price of ₹2675 (raised from ₹2575), citing continued overhang from upcoming R32 supply additions in India through CY26/27, with high earnings sensitivity as every $1/kg change in R32 prices impacts SRF’s EBITDA by nearly 7%.

 07 May 2026 09:00 AM

SRF: Citi maintains a Sell on SRF with a Target Price of ₹2675 (raised from ₹2575), citing continued overhang from upcoming R32 supply additions in India through CY26/27, with high earnings sensitivity as every $1/kg change in R32 prices impacts SRF’s EBITDA by nearly 7%.

SRF: Co. Expects 15-20% Growth Next Year Despite Unstable Global Conditions - Concall Update

 06 May 2026 11:46 AM

SRF: Co. Expects 15-20% Growth Next Year Despite Unstable Global Conditions - Concall Update

SRF: Warns About Uncertainty In Global Market Situation - Concall Update

 06 May 2026 11:40 AM

SRF: Warns About Uncertainty In Global Market Situation - Concall Update

SRF: Co's Sales To West Asia Have Been Affected; This Region Was A Key Market. - Concall Update

 06 May 2026 11:42 AM

SRF: Co's Sales To West Asia Have Been Affected; This Region Was A Key Market. - Concall Update

SRF: Approves ₹2,285 Crore Investment For New Fluorochemicals Facility In Gopalpur, Odisha, Including 20,000 MTPA HFO Plant And 30,000 MTPA AHF Plant With Additional Utilities And Infrastructure.

 05 May 2026 04:23 PM

SRF: Approves ₹2,285 Crore Investment For New Fluorochemicals Facility In Gopalpur, Odisha, Including 20,000 MTPA HFO Plant And 30,000 MTPA AHF Plant With Additional Utilities And Infrastructure.

SRF: Co's Co MD States Exports To The Middle East Were Affected This Quarter, But The Company Remains Optimistic About Future Prospects Despite Ongoing Geopolitical Uncertainty.

 05 May 2026 04:06 PM

SRF: Co's Co MD States Exports To The Middle East Were Affected This Quarter, But The Company Remains Optimistic About Future Prospects Despite Ongoing Geopolitical Uncertainty.

SRF: Q4 CONS NET PROFIT 5.8B RUPEES VS 5.3B (YOY)

 05 May 2026 04:00 PM

SRF: Q4 CONS NET PROFIT 5.8B RUPEES VS 5.3B (YOY)

SRF: Q4 EBITDA 10.3B RUPEES VS 9.57B (YOY) || Q4 EBITDA MARGIN 22.22% VS 22.2% (YOY)

 05 May 2026 04:00 PM

SRF: Q4 EBITDA 10.3B RUPEES VS 9.57B (YOY) || Q4 EBITDA MARGIN 22.22% VS 22.2% (YOY)

SRF: Q4 REVENUE 46.2B RUPEES VS 43B (YOY)

 05 May 2026 04:01 PM

SRF: Q4 REVENUE 46.2B RUPEES VS 43B (YOY)

SRF: Files Rectification And Appeals To ITAT Over ₹327.44 Cr Income Tax Demand For AY23, Citing A Technical Error; Management Expects Full Reversal With No Immediate Financial Impact

 07 Apr 2026 05:54 PM

SRF: Files Rectification And Appeals To ITAT Over ₹327.44 Cr Income Tax Demand For AY23, Citing A Technical Error; Management Expects Full Reversal With No Immediate Financial Impact

SRF: Promoter Kama Holding To Sell 3% Stake In Open Market To Be Completed By March

 17 Feb 2026 01:54 PM

SRF: Promoter Kama Holding To Sell 3% Stake In Open Market To Be Completed By March

SRF: Citi maintains 'Sell' on SRF, cuts target price to Rs 2,575.

 21 Jan 2026 09:09 AM

SRF: Citi maintains 'Sell' on SRF, cuts target price to Rs 2,575.

SRF: Jefferies on SRF U-P, target price Rs 2640

 21 Jan 2026 09:09 AM

SRF: Jefferies on SRF U-P, target price Rs 2640

SRF: Nuvama on SRF Maintain Buy with a target price of Rs 3,584 (earlier Rs 3,841)

 21 Jan 2026 09:09 AM

SRF: Nuvama on SRF Maintain Buy with a target price of Rs 3,584 (earlier Rs 3,841)

SRF: MS on SRF UW target price 2177

 21 Jan 2026 09:09 AM

SRF: MS on SRF UW target price 2177

SRF: Approves New Pharma Intermediates Plant In Dahej With ₹180 Crore Investment

 20 Jan 2026 03:25 PM

SRF: Approves New Pharma Intermediates Plant In Dahej With ₹180 Crore Investment

SRF: CO HAD A TAX ADJUSTMENT OF 1B RUPEES

 20 Jan 2026 03:18 PM

SRF: CO HAD A TAX ADJUSTMENT OF 1B RUPEES

SRF: CO DECLARES INTERIM DIVIDEND AT 5 RUPEES PER SHARE

 20 Jan 2026 03:19 PM

SRF: CO DECLARES INTERIM DIVIDEND AT 5 RUPEES PER SHARE

SRF: Q3 CONS NET PROFIT 4.3B RUPEES VS 2.71B (YOY); EST 3.81B

 20 Jan 2026 03:11 PM

SRF: Q3 CONS NET PROFIT 4.3B RUPEES VS 2.71B (YOY); EST 3.81B

SRF: Q3 EBITDA 7.8B RUPEES VS 6.2B (YOY); EST 7.66B || Q3 EBITDA MARGIN 21.01% VS 17.75% (YOY); EST 21.9%

 20 Jan 2026 03:12 PM

SRF: Q3 EBITDA 7.8B RUPEES VS 6.2B (YOY); EST 7.66B || Q3 EBITDA MARGIN 21.01% VS 17.75% (YOY); EST 21.9%